Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Jul 22;5(1):7.
doi: 10.1186/1465-9921-5-7.

Significant receptor affinities of metabolites and a degradation product of mometasone furoate

Affiliations

Significant receptor affinities of metabolites and a degradation product of mometasone furoate

Anagnostis Valotis et al. Respir Res. .

Abstract

Mometasone furoate (MF) is a highly potent glucocorticoid used topically to treat inflammation in the lung, nose and on the skin. However, so far no information has been published on the human glucocorticoid receptor activity of the metabolites or degradation products of MF. We have now determined the relative receptor binding affinities of the known metabolite 6beta-OH MF and the degradation product 9,11-epoxy MF to understand their possible contribution to undesirable systemic side effects. In competition experiments with human lung glucocorticoid receptors we have determined the relative receptor affinities (RRA) of these substances with reference to dexamethasone (RRA = 100). We have discovered that 6beta-OH MF and 9,11-epoxy MF display RRAs of 206 +/- 15 and 220 +/- 22, respectively. This level of activity is similar to that of the clinically used inhaled corticosteroid flunisolide (RRA 180 +/- 11). Furthermore we observed that 9,11-epoxy MF is a chemically reactive metabolite. In recovery experiments with human plasma and lung tissue we found a time dependent decrease in extractability of the compound. Hence, we provide data that might contribute to the understanding of the pharmacokinetics as well as the clinical effects of MF.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Recovery of mometasone furoate (MF) and its degradation product 9,11-epoxy MF from incubation mixtures with human plasma over three hours. Each data point represents the mean and mean deviation of the mean of three experiments.
Figure 2
Figure 2
Recovery of 9,11-epoxy MF from incubation mixtures with human lung tissue and buffer (control experiment) over three hours. Each data point represents the mean and mean deviation of the mean of three experiments.

Similar articles

Cited by

References

    1. Sharpe M, Jarvis B. Inhaled mometasone furoate: a review of its use in adults and adolescents with persistent asthma. Drugs. 2001;61:1325–1350. - PubMed
    1. Trangsrud AJ, Whitaker AL, Small RE. Intranasal corticosteroids for allergic rhinitis. Pharmacotherapy. 2002;22:1458–1467. doi: 10.1592/phco.22.16.1458.33692. - DOI - PubMed
    1. Brazzini B, Pimpinelli N. New and established topical corticosteroids in dermatology: clinical pharmacology and therapeutic use. Am J Clin Dermatol. 2002;3:47–58. - PubMed
    1. O'Connor B, Bonnaud G, Haahtela T, Luna JM, Querfurt H, Wegener T, Lutsky BN. Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator. Ann Allergy Asthma Immunol. 2001;86:397–404. - PubMed
    1. Würthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm Ztg Wiss. 1992;4:161–167.

Publication types

LinkOut - more resources